We analyzed the reverse transcriptase genotypes of human immunodeficiency virus type 1 subtype C viruses isolated from 23 patients in Botswana treated with didanosine-based regimens. The K65R mutation was selected either alone or together with the Q151M, S68G, or F116Y substitution in viruses from seven such individuals. The results of in vitro passage experiments were consistent with an apparent increased propensity of subtype C viruses to develop the K65R substitution.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1693987 | PMC |
| http://dx.doi.org/10.1128/AAC.00714-06 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir.
Viruses
December 2024
HIV Pathogenesis Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.
Islatravir (ISL) is the first-in-class nucleoside reverse transcriptase translocation inhibitor (NRTtI) with novel modes of action. Data on ISL resistance are currently limited, particularly to HIV-1 non-B subtypes. This study aimed to assess prevalent nucleos(t)ide reverse transcriptase inhibitor (NRTI)-resistant mutations in HIV-1 subtype C for their phenotypic resistance to ISL.
View Article and Find Full Text PDFNext-Generation Sequencing Reveals a High Frequency of HIV-1 Minority Variants and an Expanded Drug Resistance Profile among Individuals on First-Line ART.
Viruses
September 2024
Medical Research Council/Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine, Uganda Research Unit, Entebbe P.O. Box 49, Uganda.
We assessed the performance and clinical relevance of Illumina MiSeq next-generation sequencing (NGS) for HIV-1 genotyping compared with Sanger sequencing (SS). We analyzed 167 participants, 45 with virologic failure (VL ≥ 1000 copies/mL), i.e.
View Article and Find Full Text PDFOral HIV pre-exposure prophylaxis use and resistance-associated mutations among men who have sex with men and transgender persons newly diagnosed with HIV in the Netherlands: results from the ATHENA cohort, 2018 to 2022.
Euro Surveill
September 2024
The members of ATHENA national observational HIV cohort are acknowledged at the end of the article.
Article Synopsis
- In the Netherlands, since the introduction of HIV pre-exposure prophylaxis (PrEP) in 2019, about 16% of new HIV diagnoses among men who have sex with men (MSM) and transgender persons (TGP) reported prior PrEP use.
- Many individuals who did not use PrEP cited reasons like low risk perception and lack of access, highlighting barriers to its uptake.
- The study identified an increase in PrEP-associated mutations linked to resistance in new infections since 2019, but found no evidence of these mutations being transmitted to others.
HIV drug resistance: analysis of viral genotypes and mutation loci in people living with HIV in Chongqing, China (2016-2023).
AIDS Res Ther
September 2024
Department of Medical Laboratory Medicine, Chongqing Public Health Medical Center, Chongqing, China.
Article Synopsis
- A retrospective study in Chongqing analyzed HIV-1 genotype drug resistance from May 2016 to June 2023, involving 3015 people living with HIV.
- Among those tested, 46.6% were found to be resistant to at least one antiviral drug, with the highest resistance observed in non-nucleoside reverse transcriptase inhibitors (43.8%).
- Common mutations associated with resistance were identified, including V179D/E and K103N/S for NNRTIs and M184V/I for NRTIs, indicating significant drug resistance challenges in the region.
- The findings highlight the need for ongoing surveillance of HIV-1 drug resistance to manage and control the local epidemic effectively.
Viral load suppression and HIV-1 drug resistance mutations in persons with HIV on TLD/TAFED in Zambia.
PLoS One
September 2024
School of Medicine and Health Sciences, Mulungushi University, Livingstone, Zambia.
Article Synopsis
- * Out of 384 participants, 90.4% achieved viral load suppression, with a notable impact of medication adherence; those missing doses were less likely to be virally suppressed.
- * Resistance mutations were identified in some participants, particularly to lamivudine and tenofovir, with specific mutations being common among those experiencing treatment failure. *
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!